Cardiac Medication Use in ACTION for Duchenne Muscular Dystrophy Cardiomyopathy
Pediatric Cardiology · 2026
DOI: 10.1007/s00246-025-03917-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Cardiology, 2026. Verfasst von Carol A Wittlieb-Weber und 24 weiteren Autor:innen. Beteiligte Einrichtung: Perelman School of Medicine at the University of Pennsylvania, Children's Hospital of Philadelphia, 3401 Civic Center Boulevard, Philadelphia, PA, 19…. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Cardiomyopathies, Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Antagonists. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
This study seeks to understand cardiac medication use in a large cohort of males with Duchenne Muscular Dystrophy (DMD) followed prospectively with focus on current practices and adherence to consensus directed medical therapy (CDMT). DMD patients have been enrolled in the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) Dystrophinopathy Registry since 2021. Cardiac medication use was analyzed at enrollment and most recent follow-up. CDMT was defined as concurrent use of angiotensin-converting-enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB) /angiotensin receptor-neprilysin inhibitor (ARNI) plus beta-blocker (BB) plus mineralocorticoid receptor antagonist (MRA). Two hundred sixty-five males with DMD (median age 17.5 (IQR 14.5–21.5) years) were prospectively followed; median follow-up was 11.5 (IQR 6.2–15.6) months. At most recent follow-up, 153 patients (57.7%) had decreased LV systolic function, 67 (25.3% of the cohort) had moderate or severe dysfunction. For patients with moderate or severe dysfunction, CDMT was used for 49/67 (73.1%) at most recent follow-up, similar to 36/51 (70.6%) at enrollment (p = 0.92). Target doses of CDMT were achieved for 27% of males on ACEi/ARB/ARNI, 28% on BB, and 23% on MRA. Initial analysis of a prospective registry of males with DMD showed that ~ 30% of patients with moderate or severe LV dysfunction were not on CDMT at most recent follow-up and the majority did not reach target dosing. Further understanding regarding the optimal combination of cardiac medications for DMD cardiomyopathy is needed, as is a better understanding of the barriers to CDMT optimization given increasing cardiac causes of death for DMD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Perelman School of Medicine at the University of Pennsylvania, Children's Hospital of Philadelphia, 3401 Civic Center Boulevard, Philadelphia, PA, 19104, USA. wittliebc@chop.edu.
- Children's Mercy Kansas City, Kansas City, USA.
- Dell Children's Medical Center, Austin, USA.
- Arkansas Children's Hospital, Little Rock, USA.
- Boston Children's Hospital, Boston, USA.
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, USA.
Förderung
- NHLBI NIH HHS
Zitieren
APA
Wittlieb-Weber, C. A., Birnbaum, B. F., Castleberry, C. D., Cunningham, T. W., Esteso, P., Gambetta, K. E., Hayes, E. A., Hsu, D. T., Kaufman, B. D., Kroslowitz, B., Lal, A. K., Lorts, A., Martinez, H., Mokshagundam, D., Nandi, D., Parent, J. J., Raucci, F., Soares, N., Soslow, J. H., …, & Conway, J. (2026). Cardiac Medication Use in ACTION for Duchenne Muscular Dystrophy Cardiomyopathy. Pediatric Cardiology. https://doi.org/10.1007/s00246-025-03917-2
Vancouver
Wittlieb-Weber CA, Birnbaum BF, Castleberry CD, Cunningham TW, Esteso P, Gambetta KE, et al. Cardiac Medication Use in ACTION for Duchenne Muscular Dystrophy Cardiomyopathy. Pediatric Cardiology. 2026. doi:10.1007/s00246-025-03917-2
BibTeX
@article{WittliebWeber2026,
author = {Wittlieb-Weber, Carol A and Birnbaum, Brian F and Castleberry, Chesney D and Cunningham, Tyler W and Esteso, Paul and Gambetta, Katheryn E and Hayes, Emily A and Hsu, Daphne T and Kaufman, Beth D and Kroslowitz, Benjamin and Lal, Ashwin K and Lorts, Angela and Martinez, Hugo and Mokshagundam, Deepa and Nandi, Deipanjan and Parent, John J and Raucci, Frank and Soares, Nelia and Soslow, Jonathan H and Shih, Renata and Shugh, Svetlana and Villa, Chet R and Wilkens, Sarah J and Wisotzkey, Bethany L and Conway, Jennifer},
title = {Cardiac Medication Use in ACTION for Duchenne Muscular Dystrophy Cardiomyopathy},
journal = {Pediatric Cardiology},
year = {2026},
doi = {10.1007/s00246-025-03917-2}
}
EUVIMED